Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
Public ClinicalTrials.gov record NCT04743804. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated With a Trigger
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger. Participants will be randomized to receive either ravulizumab plus best supportive care or placebo plus best supportive care. The treatment period is 26 weeks followed by a 26-week off-treatment follow-up period.
Study identification
- NCT ID
- NCT04743804
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2021
- Primary completion
- Dec 21, 2022
- Completion
- Dec 21, 2022
- Last update posted
- Sep 30, 2024
2021 – 2022
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85724 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Gainesville | Florida | 32610 | — |
| Research Site | Lexington | Kentucky | 40536 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Boston | Massachusetts | 02111 | — |
| Research Site | Boston | Massachusetts | 02115 | — |
| Research Site | Boston | Massachusetts | 02118 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Valhalla | New York | 10595 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Cleveland | Ohio | 44106 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Columbus | Ohio | 43203 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Salt Lake City | Utah | 84115 | — |
| Research Site | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 77 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04743804, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04743804 live on ClinicalTrials.gov.